Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Spectral Medical Inc
T.EDT
Alternate Symbol(s):
EDTXF
Healthcare
Biotechnology
Medical Instruments & Supplies
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the...
bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
TSX:EDT - Post Discussion
Spectral Medical Inc
> 2 milllions for 10 years exclusivity
New Post
View:
Discussion
List
(144)
•••
Stocktree
X
View Profile
View Bullboard History
Post by
Stocktree
on Feb 22, 2024 10:41am
2 milllions for 10 years exclusivity
That's $200 k a year.
Spectral is really expecting a massive roll out of its "game changer".
(192)
•••
BayStreetWild
X
View Profile
View Bullboard History
Comment by
BayStreetWild
on Feb 22, 2024 10:48am
Well... You have to add up all the milestone payments. I always knew that it would be at most 5M total for this payment from which they already drew.. so not surprised here. Data would be the game changer for the investing community.. but that doesn't seem to be coming. The trial is back on track so there's that going for Spectral. I can see this hitting 300-400M market cap on speculation
...more
(144)
•••
Stocktree
X
View Profile
View Bullboard History
Comment by
Stocktree
on Feb 22, 2024 10:55am
If Baxter hadn't paid this 2 million, it would have lost its exclusivity, according to the communique. That would have been a catastrophic assessment of PMX's effectiveness and value. They paid the first sums to have direct access to the data, and once they saw the data, were comfortable enough to offer 2 million for the goods for 10 years. If you still expect this device to hit the
...more
(214)
•••
palinc2000
X
View Profile
View Bullboard History
Comment by
palinc2000
on Feb 22, 2024 12:13pm
The milestone payment was used as a carrot ahead of the 90 patient milestone and was not even mentioned in the PR....So Baxter will keep the exclusive right to distribute into a MULTI BILLION$ POTENTIAL MARKET for a period of 10 years for a mere 2 million canadian dollrs....No wonder they omitted to disclose that in yesterdays PR We also learned this morning that at least 15
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments